<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30201">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713542</url>
  </required_header>
  <id_info>
    <org_study_id>Arthrex 004</org_study_id>
    <nct_id>NCT02713542</nct_id>
  </id_info>
  <brief_title>Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)</brief_title>
  <official_title>Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthrex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arthrex, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is primarily investigating the effectiveness of Autologous Conditioned Plasma
      (ACP) Intra-articular (IA) in patients with Osteoarthritis (OA) in the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multi center randomized double blind, two arm study.

      90 subjects will be randomized to receive injections of either Autologous Conditioned Plasma
      Intra-articular or the control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores measured by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) survey.</measure>
    <time_frame>6 month visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores measured by the WOMAC survey.</measure>
    <time_frame>2, 3 and 12 month visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stiffness score measured by the WOMAC survey.</measure>
    <time_frame>6 month visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function scores measured by the WOMAC survey.</measure>
    <time_frame>2, 3 and 12 month visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stiffness scores measured by the WOMAC survey.</measure>
    <time_frame>2, 3 and 12 month visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Autologous Conditioned Plasma (ACP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Intra-articular (IA) injections at 1 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline (NS)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 NS Intra-articular (IA) injections at 1 week intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACP</intervention_name>
    <description>Autologous Conditioned Plasma</description>
    <arm_group_label>Autologous Conditioned Plasma (ACP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three Normal Saline IA injections of 3-8 mL at 1-week intervals.</description>
    <arm_group_label>Normal Saline (NS)</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is 18 to 70 years of age.

          2. The subject presents with complaints of continued pain of primary knee for at least 6
             weeks.

          3. The subject has documented radiographs evidence of Osteoarthritis (OA) in the
             tibio-femoral or patella-femoral compartment of the target knee (Kellgren-Lawrence
             Grades II-III), using radiographs performed within 24 weeks of screening.

          4. The subject has a WOMAC pain score of at least 8 out of 20 and at least moderate pain
             (a score of 2) for at least 2 questions on activities

        Exclusion Criteria:

          1. Grade I and IV on the knee Kellgren-Lawrence grading scale

          2. Subject has clinically 3+ effusion of the target knee (stroke test grading system).

          3. Subject has significant (&gt; 10‚Å∞) valgus or varus deformities as evidenced by standard
             of care X-ray.

          4. Subject has had systemic or IA injection of corticosteroids in any joint within three
             months prior to screening.

          5. Viscosupplementation in any joint in the past six months.

          6. Subject has an increased risk for post- procedure bleeding (e.g., bleeding disorder
             or taking anticoagulants except low-dose aspirin).

          7. Subject had prior open surgery on the target knee within 12 months or knee
             arthroscopy within 6 months

          8. Subject has inflammatory disease of either knee other than OA.

          9. Subject with underlying medical conditions that could interfere with the evaluation
             of the outcome.

         10. Subject with positive pregnancy test, or breast feeding.

         11. Subject with plans to participate in other clinical trial involving medical or
             surgical intervention in the next 12 months.

         12. Subject with any condition (including cognitive impairment) that, in the opinion of
             the investigator, might interfere with the evaluation of the study objectives.

         13. Subject has rheumatoid arthritis or gout

         14. Subject has a history of or a current infection at the affected joint.

         15. Subject with plans to undergo any elective orthopedic surgery in the next 12 months.

         16. Subject requires pain management therapy (with the exception of acetaminophen) not
             related to the target knee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbias Orthopedic Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa C Hirschberg, RN BSN</last_name>
    <phone>2395984302</phone>
    <phone_ext>71122</phone_ext>
    <email>melissa.hirschberg@arthrex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kavita Ahuja</last_name>
      <phone>312-912-4701</phone>
      <email>sports.research@rushortho.com</email>
    </contact>
    <investigator>
      <last_name>Adam Yanke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Cole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedSport University of Michigan Sports Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Enselman</last_name>
      <phone>734-930-7386</phone>
      <email>esibisk@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jaimee Gauthier</last_name>
      <email>jaimeeg@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Asheesh Bedi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tariq M Awan, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Orthopedics -Chesterfield</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Columbia Orthopedic Group</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Bley</last_name>
      <phone>573-262-0104</phone>
      <email>J_bley@me.com</email>
    </contact>
    <investigator>
      <last_name>Patrick Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawkins Foundation</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Newton</last_name>
      <phone>864-454-7458</phone>
      <email>Eric.Newton@hawkinsfoundation.com</email>
    </contact>
    <contact_backup>
      <last_name>Allyson Sandago</last_name>
      <email>Allyson.sandago@hawkinsfoundation.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>February 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
